Northern Trust’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-324,786
| Closed | -$601K | – | 4651 |
|
|
2023
Q1 | $601K | Sell |
324,786
-31,852
| -9% | -$39.5K | ﹤0.01% | 3388 |
|
|
2022
Q4 | $396K | Buy |
356,638
+23,482
| +7% | +$33.4K | ﹤0.01% | 3579 |
|
|
2022
Q3 | $779K | Sell |
333,156
-56,124
| -14% | -$199K | ﹤0.01% | 3371 |
|
|
2022
Q2 | $1.18M | Buy |
389,280
+56,692
| +17% | +$276K | ﹤0.01% | 3301 |
|
|
2022
Q1 | $2.26M | Sell |
332,588
-14,134
| -4% | -$101K | ﹤0.01% | 3043 |
|
|
2021
Q4 | $2.89M | Sell |
346,722
-3,925
| -1% | -$32.3K | ﹤0.01% | 3028 |
|
|
2021
Q3 | $2.6M | Sell |
350,647
-77,238
| -18% | -$478K | ﹤0.01% | 3137 |
|
|
2021
Q2 | $2.91M | Buy |
427,885
+175,285
| +69% | +$1.46M | ﹤0.01% | 3173 |
|
|
2021
Q1 | $2.59M | Sell |
252,600
-61,040
| -19% | -$669K | ﹤0.01% | 3112 |
|
|
2020
Q4 | $2.2M | Buy |
313,640
+4,069
| +1% | +$31.7K | ﹤0.01% | 3154 |
|
|
2020
Q3 | $2.53M | Sell |
309,571
-13,601
| -4% | -$84.3K | ﹤0.01% | 2946 |
|
|
2020
Q2 | $2.23M | Buy |
323,172
+126,893
| +65% | +$684K | ﹤0.01% | 2985 |
|
|
2020
Q1 | $932K | Buy |
196,279
+23,686
| +14% | +$136K | ﹤0.01% | 3247 |
|
|
2019
Q4 | $1.51M | Sell |
172,593
-8,164
| -5% | -$44.1K | ﹤0.01% | 3254 |
|
|
2019
Q3 | $602K | Sell |
180,757
-8,606
| -5% | -$34.5K | ﹤0.01% | 3510 |
|
|
2019
Q2 | $937K | Buy |
189,363
+5,604
| +3% | +$29.8K | ﹤0.01% | 3379 |
|
|
2019
Q1 | $1.14M | Sell |
183,759
-65
| -0% | -$314 | ﹤0.01% | 3314 |
|
|
2018
Q4 | $619K | Sell |
183,824
-1,855
| -1% | -$8.67K | ﹤0.01% | 3506 |
|
|
2018
Q3 | $1.21M | Buy |
185,679
+24,322
| +15% | +$181K | ﹤0.01% | 3423 |
|
|
2018
Q2 | $1.24M | Buy |
161,357
+15,684
| +11% | +$226K | ﹤0.01% | 3404 |
|
|
2018
Q1 | $3.26M | Sell |
145,673
-4,512
| -3% | -$100K | ﹤0.01% | 2836 |
|
|
2017
Q4 | $1.92M | Buy |
150,185
+5,606
| +4% | +$82.4K | ﹤0.01% | 3163 |
|
|
2017
Q3 | $2.25M | Buy |
144,579
+54,167
| +60% | +$766K | ﹤0.01% | 3101 |
|
|
2017
Q2 | $1.27M | Buy |
90,412
+57,120
| +172% | +$1.22M | ﹤0.01% | 3374 |
|
|
2017
Q1 | $732K | Buy |
+33,292
| New | +$705K | ﹤0.01% | 3439 |
|
Other funds holding JNCE
Northern Trust's JNCE Position: Q2 2023 in Review
Northern Trust sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 324,786 shares — an estimated $601K sold.
Northern Trust first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $3.26M in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Northern Trust reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Northern Trust sold 324,786 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $601K.
- Northern Trust first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Northern Trust's Jounce Therapeutics, Inc. Common Stock position peaked at $3.26M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.